Department of Hematology, Taihe Hospital, Hubei University of Medicine, Hubei, China.
Children's Medical Center, Taihe Hospital, Hubei University of Medicine, Hubei, China.
Ir J Med Sci. 2024 Feb;193(1):17-25. doi: 10.1007/s11845-023-03410-w. Epub 2023 Jun 19.
Circular RNA_0007841 (Circ_0007841) facilitates multiple myeloma (MM) progression and resistance of the bortezomib by experimental studies, while its clinical implication in MM patients is still unclear. This study intended to evaluate the longitudinal change and prognostic role of circ_0007841 expression in MM patients receiving bortezomib-based induction therapy.
In this prospective study, bone marrow plasma cell (BMPC) samples were gained from 97 MM patients at diagnosis and after bortezomib-based induction therapy, and from 30 healthy controls (HCs) proposing BM donation. Then, circ_0007841 expression in BMPC samples was measured by reverse transcription-quantitative polymerase chain reaction. Additionally, MM patients were followed up for a median of 29.4 months.
Circ_0007841 expression was increased in MM patients compared to HCs (P < 0.001), but it was decreased after bortezomib-based induction therapy in MM patients (P < 0.001). Moreover, circ_0007841 expression at diagnosis was associated with the presence of t (4; 14) (P = 0.034), while its expression after bortezomib-based induction therapy was linked with higher revised international staging system stage (P = 0.025) in MM patients. Interestingly, circ_0007841 expression after bortezomib-based induction therapy was lower in MM patients who achieved complete remissions (P = 0.001) and overall responses (P = 0.002) compared to those who did not. Prognostically, circ_0007841 expression after bortezomib-based induction therapy (over the median vs. below the median) independently predicted shorter progression-free survival (hazard ratio (HR): 2.497, P = 0.002) and overall survival (HR: 3.107, P = 0.008) in MM patients.
Circ_0007841 quantification during induction therapy may reflect the response and survival benefits to bortezomib-based regimen in MM patients.
通过实验研究发现，环状 RNA_0007841（Circ_0007841）促进多发性骨髓瘤（MM）的进展和硼替佐米的耐药性，但其在 MM 患者中的临床意义尚不清楚。本研究旨在评估 MM 患者接受硼替佐米为基础的诱导治疗时，骨髓浆细胞（BMPC）中 circ_0007841 表达的纵向变化及其预后作用。
在这项前瞻性研究中，从 97 例 MM 患者和 30 例健康对照者（HC）的诊断和硼替佐米为基础的诱导治疗后的骨髓浆细胞样本中，以及从提出骨髓捐献的 30 例健康对照者中获得 circ_0007841 表达的逆转录定量聚合酶链反应。此外，对 MM 患者进行了中位数为 29.4 个月的随访。
与 HC 相比，MM 患者的 circ_0007841 表达升高（P<0.001），但在 MM 患者接受硼替佐米为基础的诱导治疗后降低（P<0.001）。此外，MM 患者诊断时的 circ_0007841 表达与 t（4; 14）的存在有关（P=0.034），而硼替佐米为基础的诱导治疗后，其表达与较高的修订国际分期系统分期有关（P=0.025）。有趣的是，与未达到完全缓解（CR）和总反应（OR）的患者相比，达到 CR 和 OR 的 MM 患者硼替佐米为基础的诱导治疗后 circ_0007841 表达较低（P=0.001 和 P=0.002）。预后分析显示，硼替佐米为基础的诱导治疗后 circ_0007841 表达（中位数以上与中位数以下）独立预测 MM 患者无进展生存期（HR：2.497，P=0.002）和总生存期（HR：3.107，P=0.008）较短。
在诱导治疗期间定量检测 circ_0007841 可能反映 MM 患者对硼替佐米为基础方案的反应和生存获益。
